Table 3.
Factors associated with virologic non‐suppression and loss to follow up at 24 months among pregnant females who initiate ART at the ages of 15–19 years
| Virologic non‐suppression | Loss to follow up | |||
|---|---|---|---|---|
| Patient characteristics | Adjusted sub‐distribution hazard ratios (aSHRs) a | 95% confidence interval | Adjusted sub‐distribution hazard ratios (aSHRs) a | 95% confidence interval |
| Age, years, at ART initiation | ||||
| 15–17 years | 1 | 1 | ||
| 18 years | 0.66 | 0.34, 1.29 | 1.17 | 0.86, 1.58 |
| 19 years | 0.66 | 0.36, 1.21 | 0.99 | 0.74, 1.33 |
| WHO Stage at ART initiation | ||||
| 1&2 | 1 | 1 | ||
| 3&4 | 1.25 | 0.37, 4.28 | 0.52 | 0.28, 0.99 |
| CD4 count (cells/μl) at ART initiation | ||||
| ≤200 | 1 | 1 | ||
| 201–350 | 0.62 | 0.33, 1.18 | 0.88 | 0.56, 1.37 |
| 351–500 | 0.31 | 0.15, 0.65 | 1.29 | 0.83, 2.03 |
| ≥500 | 0.11 | 0.05, 0.27 | 1.43 | 0.93, 2.20 |
| Year of ART initiation | ||||
| 2004–2012 | 1 | 1 | ||
| 2013–2015 | 1.73 | 0.69, 4.34 | 0.88 | 0.62, 1.26 |
| 2016–2019 | 2.07 | 0.78, 5.43 | 1.11 | 0.76, 1.61 |
a
Adjusted for health facility where the patients initiated ART.
Bold figures represent effect estimates that were significant at the 5%. level of significance.